Rationale for immune-based therapies for HIV-1 infection

[1] ABOULAFIA D, 1989, J ACQ IMMUN DEF SYND, V2, P54

[2] CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1 [J]. SCIENCE, 1996, 272 (5270) : 1955 - 1958

[3] SERUM LEVELS OF TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) AND SOLUBLE TNF RECEPTORS IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION - CORRELATIONS TO CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL PARAMETERS [J]. JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (02) : 420 - 424

[4] Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease [J]. SCIENCE, 1997, 277 (5322) : 112 - 116

[5] BEX F, 1994, BLOOD, V84, P3317

[6] Serum cytokine profiles in acute primary HIV-1 infection and in infectious mononucleosis [J]. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1996, 78 (01): : 61 - 69

[7] GENE-THERAPY IN PERIPHERAL-BLOOD LYMPHOCYTES AND BONE-MARROW FOR ADA(-) IMMUNODEFICIENT PATIENTS [J]. SCIENCE, 1995, 270 (5235) : 470 - 475

[8] VIRUS-SPECIFIC CD8+ CYTOTOXIC T-LYMPHOCYTE ACTIVITY ASSOCIATED WITH CONTROL OF VIREMIA IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J]. JOURNAL OF VIROLOGY, 1994, 68 (09) : 6103 - 6110

[9] INTERLEUKIN-2 PRODUCTION AND RESPONSIVENESS IN INDIVIDUALS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME AND THE GENERALIZED LYMPHADENOPATHY SYNDROME [J]. CELLULAR IMMUNOLOGY, 1987, 104 (01) : 142 - 153

[10] BRIDGES SH, 1995, LANCET, V345, P427, DOI 10.1016/S0140-6736(95)90407-7

[1] ABOULAFIA D, 1989, J ACQ IMMUN DEF SYND, V2, P54

[2] CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1 [J]. SCIENCE, 1996, 272 (5270) : 1955 - 1958

[3] SERUM LEVELS OF TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) AND SOLUBLE TNF RECEPTORS IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION - CORRELATIONS TO CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL PARAMETERS [J]. JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (02) : 420 - 424

[4] Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease [J]. SCIENCE, 1997, 277 (5322) : 112 - 116

[5] BEX F, 1994, BLOOD, V84, P3317

[6] Serum cytokine profiles in acute primary HIV-1 infection and in infectious mononucleosis [J]. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1996, 78 (01): : 61 - 69

[7] GENE-THERAPY IN PERIPHERAL-BLOOD LYMPHOCYTES AND BONE-MARROW FOR ADA(-) IMMUNODEFICIENT PATIENTS [J]. SCIENCE, 1995, 270 (5235) : 470 - 475

[8] VIRUS-SPECIFIC CD8+ CYTOTOXIC T-LYMPHOCYTE ACTIVITY ASSOCIATED WITH CONTROL OF VIREMIA IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J]. JOURNAL OF VIROLOGY, 1994, 68 (09) : 6103 - 6110

[9] INTERLEUKIN-2 PRODUCTION AND RESPONSIVENESS IN INDIVIDUALS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME AND THE GENERALIZED LYMPHADENOPATHY SYNDROME [J]. CELLULAR IMMUNOLOGY, 1987, 104 (01) : 142 - 153

[10] BRIDGES SH, 1995, LANCET, V345, P427, DOI 10.1016/S0140-6736(95)90407-7